Preparation method of azilsartan intermediate and azilsartan

An intermediate and time technology, which is applied in the field of synthesizing the intermediate of antihypertensive drug Azisartan and the preparation field of Azisartan, can solve the problems of long reaction time, low process yield, many impurities and the like

Inactive Publication Date: 2014-03-26
SHANGHAI INST OF PHARMA IND CO LTD +1
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The technical problem to be solved by the present invention is to provide a kind of azilsartan intermediate and its combination The preparation method of Azilsartan 1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of azilsartan intermediate and azilsartan
  • Preparation method of azilsartan intermediate and azilsartan
  • Preparation method of azilsartan intermediate and azilsartan

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Preparation of compound (3B)

[0085] 15.2 g of the raw material (compound 2B) was placed in a reaction flask, 150 ml of ethanol, 3.6 g of triethylamine, and 28 ml of 50% aqueous hydroxylamine solution were added, reacted for 7 hours, cooled and crystallized to obtain 14.1 g (86.0%) of a white solid. The main amide impurity (compound 6B) in the reaction solution was detected by HPLC at the end of the reaction: the product was 2.55%: 97.44% (that is, the ratio of impurity to product was 1:38.2), see figure 1 .

[0086] Table 1: figure 1 Analysis of HPLC detection data

[0087]

[0088] The mass spectrum shows: the molecular ion peak [M+1] is 459.

[0089] 1 HNMR spectrum (DMSO-d6): δppm 1.1-1.3 (3H, t), 1.3-1.4 (3H, t), 3.2-3.3 (2H), 4.1-4.3 (2H, q), 4.5-4.7 (2H, q ), 5.4-5.5 (1H, s), 5.5-5.6 (2H, s), 6.9-7.8 (11H, m).

[0090] Melting point: 210-212°C.

[0091] Impurity 6B

[0092] Mass spectrum shows: molecular ion peak [M+1] is 444;

[0093] Melting point:...

Embodiment 2

[0095] Preparation of compound (3B)

[0096] 15.0 g of raw material (compound 2B) was placed in a reaction flask, 150 ml of ethanol, 1.8 g (2.5 mL) of triethylamine, and 30 ml of 50% aqueous hydroxylamine solution were added, reacted for 10 h, cooled and crystallized, and 15.4 g (95.2%) of a white solid was obtained. . The main amide impurity (compound 6B) in the reaction solution was detected by HPLC at the end of the reaction: the product was 2.55%:97.44% (that is, the ratio of impurities to product was 1:38.2), and the purity of the product detected by HPLC after cooling and crystallization was 98.49%.

Embodiment 3

[0105] Preparation of compound (3B)

[0106] 7.5 g of the raw material (compound 2B) was placed in a reaction flask, 50 ml of ethanol and 15 ml of 50% aqueous hydroxylamine solution were added, reacted for 10 h, cooled and crystallized to obtain 6.2 g (76.0%) of a white solid. The main amide impurity (compound 6B) in the reaction solution detected by HPLC: the product is 12.16%: 87.83%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses a preparation method of an intermediate 5B and azilsartan 1. The preparation method of the azilsartan 1 comprises the following steps: 1) in a solvent, mixing a compound 2B with hydroxylamine to react to obtain a compound 3B; 2) in a solvent, mixing the compound 3B prepared in the step 1) with chloroformate to react under the action of alkali to obtain a compound 4B; 3) in a solvent, carrying out cyclization reaction on the compound 4B prepared in the step 2) to obtain a compound 5B; and 4) in a solvent, carrying out esterolysis reaction on the compound 5B prepared in the step 3) under the action of alkali to obtain the azilsartan 1, wherein R is a C6-C10 aryl group or C1-C4 straight-chain or branched-chain alkyl group. The preparation method of the azilsartan intermediate 5B is described as the step 3). The preparation method has the advantages of fewer impurities, short reaction time, higher technical yield and higher product purity, and is suitable for industrial production.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to an intermediate for synthesizing antihypertensive drug Azilsartan (Azilsartan compound 1) and a preparation method thereof. Background technique [0002] Azilsartan is the latest antihypertensive drug on the market, developed by Takeda Pharmaceutical, and was approved in Japan on January 28, 2012. Azilsartan is a selective angiotensin Ⅱ receptor antagonist, which can competitively and reversibly block the combination of angiotensin and AT1 receptors to lower blood pressure. The affinity for AT1 receptors is More than 10,000 times the AT2 receptor, because it does not inhibit ACE, it will not affect the level of bradykinin, nor will it bind to and block other receptors or ion channels related to vascular regulation. Azilsartan's ability to bind to human AT1 receptors is 2 times and 30 times that of olmesartan and angiotensin II, respectively. Clinical studies have shown that a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D413/10
CPCC07D413/10
Inventor 王小梅隋强唐超刘帅欧阳群香时惠麟
Owner SHANGHAI INST OF PHARMA IND CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap